Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

80 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Odanacatib, a selective cathepsin K inhibitor to treat osteoporosis: safety, tolerability, pharmacokinetics and pharmacodynamics--results from single oral dose studies in healthy volunteers.
Stoch SA, Zajic S, Stone JA, Miller DL, van Bortel L, Lasseter KC, Pramanik B, Cilissen C, Liu Q, Liu L, Scott BB, Panebianco D, Ding Y, Gottesdiener K, Wagner JA. Stoch SA, et al. Among authors: panebianco d. Br J Clin Pharmacol. 2013 May;75(5):1240-54. doi: 10.1111/j.1365-2125.2012.04471.x. Br J Clin Pharmacol. 2013. PMID: 23013236 Free PMC article. Clinical Trial.
Effect of CYP3A Inhibition and Induction on the Pharmacokinetics of Suvorexant: Two Phase I, Open-Label, Fixed-Sequence Trials in Healthy Subjects.
Wrishko RE, McCrea JB, Yee KL, Liu W, Panebianco D, Mangin E, Chakravarthy M, Martinez-Cantarin MP, Kraft WK. Wrishko RE, et al. Among authors: panebianco d. Clin Drug Investig. 2019 May;39(5):441-451. doi: 10.1007/s40261-019-00764-x. Clin Drug Investig. 2019. PMID: 30810914 Free PMC article. Clinical Trial.
Pharmacokinetic Drug-Drug Interactions Between Letermovir and the Immunosuppressants Cyclosporine, Tacrolimus, Sirolimus, and Mycophenolate Mofetil.
McCrea JB, Macha S, Adedoyin A, Marshall W, Menzel K, Cho CR, Liu F, Zhao T, Levine V, Kraft WK, Yoon E, Panebianco D, Stoch SA, Iwamoto M. McCrea JB, et al. Among authors: panebianco d. J Clin Pharmacol. 2019 Oct;59(10):1331-1339. doi: 10.1002/jcph.1423. Epub 2019 Apr 16. J Clin Pharmacol. 2019. PMID: 30990905 Clinical Trial.
Drug-Drug Interaction of Letermovir and Atorvastatin in Healthy Participants.
McCrea JB, Menzel K, Adedoyin A, Cho CR, Fox-Bosetti S, Macha S, Zhao T, Liu F, Panebianco D, Stoch SA, Iwamoto M. McCrea JB, et al. Among authors: panebianco d. Clin Pharmacol Drug Dev. 2022 Apr;11(4):420-428. doi: 10.1002/cpdd.1071. Epub 2022 Feb 14. Clin Pharmacol Drug Dev. 2022. PMID: 35157785
Single- and multiple-dose pharmacokinetics and tolerability of telcagepant, an oral calcitonin gene-related peptide receptor antagonist, in adults.
Han TH, Blanchard RL, Palcza J, McCrea JB, Laethem T, Willson K, Xu Y, Ermlich S, Boyle J, Lines C, Gutierrez M, Van Bortel L, Xiao AJ, Sinclair S, Hickey L, Panebianco D, Murphy MG. Han TH, et al. Among authors: panebianco d. J Clin Pharmacol. 2010 Dec;50(12):1367-76. doi: 10.1177/0091270010361741. Epub 2010 Feb 19. J Clin Pharmacol. 2010. PMID: 20173082 Clinical Trial.
Correction to: Effect of CYP3A Inhibition and Induction on the Pharmacokinetics of Suvorexant: Two Phase I, Open-Label, Fixed-Sequence Trials in Healthy Subjects.
Wrishko RE, McCrea JB, Yee KL, Liu W, Panebianco D, Mangin E, Chakravarthy M, Martinez-Cantarin MP, Kraft WK. Wrishko RE, et al. Among authors: panebianco d. Clin Drug Investig. 2019 May;39(5):453-454. doi: 10.1007/s40261-019-00777-6. Clin Drug Investig. 2019. PMID: 30895461 Free PMC article.
80 results